HC Wainwright cut shares of iTeos Therapeutics (NASDAQ:ITOS – Free Report) from a buy rating to a neutral rating in a research note issued to investors on Wednesday, MarketBeat.com reports.

Leerink Partnrs downgraded shares of iTeos Therapeutics (NASDAQ:ITOS – Free Report) from a strong-buy rating to a hold rating in a report published on Wednesday morning,Zacks.com reports.

Teos and GSK were the last to report a new setback in TIGIT targeting for non-small cell lung cancer patients. Read why I am ...

Almost a third of Americans are more than a year behind in cancer screening, more than half of them because of out-of-pocket ...

Pharmaceutical share prices fell last Monday, after US President Donald Trump vowed to reduce drug prices in the USA by as ...

A new generation of checkpoint inhibitors is emerging, with some showing more promise than others. From recent TIGIT failures ...

iTeos Therapeutics has said it is evaluating with partner GlaxoSmithKline whether to conduct additional clinical trials of TIGIT drug EOS-448 following the failure of a key trial for Roche's rival ...

Our round-up of notable biotech financings in the last week includes a $120 million direct offering for immunology and inflammation biotech iTeos, and private rounds for Lycia, Attovia ...